Ampersand Capital acquires Purna Pharmaceuticals
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage…
13 Feb 2026
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Amgen has secured approval from the European Commission (EC) for Uplizna (inebilizumab) as an add-on treatment to standard therapy for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor…
12 Feb 2026
Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head
Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it would not renew existing CEO Paul Hudson’s contract. The abrupt…
12 Feb 2026
Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal
Madrigal Pharmaceuticals has inked a deal worth up to $4.4bn with Chinese biotech Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals in a bid to expand offerings in the…
12 Feb 2026
Citius Oncology and Uniphar sign European distribution deal for Lymphir
Citius Pharmaceuticals' subsidiary Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir (denileukin diftitox-cxdl) in selected European countries. The agreement focuses on expanding Lymphir’s…
12 Feb 2026
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), along with paclitaxel, with or without bevacizumab, for ovarian…
11 Feb 2026
Mexico enlists Moderna to boost mRNA supply for respiratory diseases
The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its vaccine offerings against respiratory diseases. As per the five-year agreement,…